Vilya logo

Vilya

vilyatx.com

Vilya uses AI-driven computational design to generate novel macrocycle drugs for human diseases. Its medicines are designed to combine the target precision of biologics with the convenience of oral dosing, including for diseases that are difficult to treat with existing drugs.

Facts

HQ
Seattle, Washington, USA
Sectors
Biotechnology, Drug discovery, Artificial intelligence
Founders
David Baker, Gaurav Bhardwaj, Lance Stewart, Patrick Salveson, Adam Moyer, Nao Hiranuma

Is this your organization? Claim it

Helion Breaks Ground on Fusion Plant; Microsoft Reports $75 Billion Azure Revenue and Beats Expectations; Seattle Startups Highlighted

Helion Energy has begun construction on a potential first commercial fusion power plant, while Microsoft revealed its Azure annual revenue of $75 billion and beat earnings expectations in the June quarter. Additionally, Seattle’s tech and startup scene is highlighted by AI company growth and Flyhomes securing $15 million to pivot its real estate business.

Vilya Secures $71 Million Series A Funding Led by NVIDIA, ARCH, Madrona, and Menlo Ventures for AI-Driven Macrocyclic Drug Development

Vilya, a biotech startup developing macrocyclic drugs using AI and machine learning, announced an expanded $71 million Series A funding round led by ARCH Venture Partners, NVIDIA's NVentures, Madrona, and Menlo Ventures. The company, a spinout from Seattle's Institute for Protein Design, aims to revolutionize drug discovery with advanced protein engineering technologies.

See all 5 news stories about Vilya.

Online